PRECIGEN INC (PGEN)
Health Care · Biotechnology · NASDAQ
A commercial-stage precision medicine company leveraging proprietary adenoviral and CAR-T platforms to address intractable diseases, notably including the FDA-approved RRP therapy Papzimeos.
What PRECIGEN INC does
Precigen is a commercial-stage biopharmaceutical company that develops precision medicine therapies using proprietary gene and cell technology platforms. Its primary focus is the advancement of treatments for immuno-oncology, autoimmune disorders, and infectious diseases, anchored by its first FDA-approved therapy, Papzimeos, for recurrent respiratory papillomatosis (RRP). The company utilizes gene delivery platforms including AdenoVerse, UltraCAR-T, and ActoBiotics to create therapeutics with controlled gene expression.
Themes: precision medicine, gene therapy, immuno-oncology, cell therapy, infectious diseases, adenoviral vectors, rare diseases
Fundamentals
- Price$7.20 as of 2026-08-21 close
- Market cap$2.6B as of 2026-08-21
- 1-year return+97.8% 2025-08-21 close $3.64 → 2026-08-21 close $7.20
- P/En/a negative earnings
- Net margin-184.0% as of 2026-08-24
- Gross margin+90.7% as of 2026-08-24
- ROE-498.3% as of 2026-08-24
- Debt / equity2.15 as of 2026-08-24
- Revenue growth (YoY)+146.7% FY2025 vs FY2024, SEC XBRL
- Revenue CAGR (3y)-28.9% SEC XBRL
- Beta0.99 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How PGEN compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
PGEN is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
55.4 #456 of 1,704 scored · #89 of 240 in Health Care
Trend 85th: it is trading 30.4% above its 50-day average, the short-term trend line; volume and participation 81st: trading volume is about normal versus its 30-day average; weakest is setup 35th: over the past year its closes ranged, and it has retraced essentially none of its move over the past year — 0% of it. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How PRECIGEN INC looks technically
PRECIGEN INC (PGEN) is trading 60.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 62 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It made a new 20-day high about 2 trading days ago. It is 4.0% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 60.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +60.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.78 | $5.78 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.50 | $4.50 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 6.08. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 62 trading days ago — a "golden cross", a bullish long-term signal | 62 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with buyers in control | 31.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 63.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($6.08 to $7.50) — its "stochastic" reading is 79 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 78.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.50 | $7.50 |
|---|---|---|
| From the 52-week high | it is 4.0% below its 52-week high (its highest price of the past year) | -4.0% |
| Above the 52-week low | it is 299.0% above its 52-week low (its lowest price of the past year) | +299.0% |
| Below the 52-week high | it is 4.0% below its highest point of the past year | 4.0% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $69.45 (set on 2015-08-06) | $69.45 |
| Given back of the 52-week move | over the past year its closes ranged ($1.85 to $7.44), and it has given back only a small part of its rise from last year’s low — 4% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.81 to $3.99. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 4.3% |
| From the all-time high | it is 89.6% below its all-time high | -89.6% |
| Nearest price level | it is trading 15.8% above a support level at $6.06 — a price it turned at twice since 2026-06-29, most recently on 2026-08-14. Since 2024-08-21 it has 15 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -15.8% |
| All-time low | its lowest closing price on record is $0.6513 (set on 2024-12-16) | $0.6513 |
| Above the all-time low | it is 1005.5% above its all-time low | +1,005% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 60th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4199 between its high and its low — about 5.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4199 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.38 and $7.73 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.38 – $6.56 – $7.73 |
| Typical daily range (% of price) | its price moves about 5.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 6.4 daily ranges above its 200-day average price (60.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.84× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Open gap | it gapped 3.3% above the previous close 2 sessions ago and has not traded back through the level it left behind at 6.75 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.3% |
| Gap filled | a 2.6% gap down opened on 2026-08-14 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 4 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 28.8 percentage points (the stock gained 31.1% while the market gained 2.3%) | +28.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 65.1 percentage points (the stock gained 68.2% while the market gained 3.1%) | +65.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 53.3 percentage points (the stock gained 64.4% while the market gained 11.1%) | +53.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 77.3 percentage points (the stock gained 97.8% while the market gained 20.5%) | +77.3% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 42% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.0% of the share price. | +42.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 51% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.77 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +51.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $6.85 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +5.1% |
Price levels it has turned at before
PGEN last closed at $7.20 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.06 | Support | 15.8% below the last close | turned there twice · 2026-06-29 to 2026-08-14 |
| $5.21 | Support | 27.7% below the last close | turned there three times · 2025-09-03 to 2026-07-01 |
| $4.99 | Support | 30.8% below the last close | turned there twice · 2026-01-07 to 2026-02-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $6.08.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $7.64 and $10.17 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · in a strong, established uptrend (ADX) · beating the market · Stretched far above its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$14.50 range $11.00 – $18.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["History of significant operating losses and high cash burn rate.","Dependence on clinical and commercial success of a limited product pipeline.","Intense competition in the biotechnology and gene therapy landscape."]
What changed in the latest 10-Q
AI-assisted comparison of PGEN's 10-Q filed 2026-05-13 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-13) describes PGEN as 'commercial-stage biopharmaceutical company' versus older filing (2025-11-13) which describes it as 'biopharmaceutical company'
- Newer filing (2026-05-13) states 'Following the FDA-approval, we launched Papzimeos in the United States as the first and only FDA approved treatment for adults with RRP'
- Newer filing (2026-05-13) includes specific market estimate: 'We estimate that there are approximately 27,000 adult patients in the United States living with RRP'
- Newer filing (2026-05-13) references submitted MAA: 'We submitted a Marketing Authorization Application ("MAA") for zopapogene imadenovec-drba for the treatment of adults with RRP to the European Medicines Agency ("EMA"). The MAA has been validated by the EMA and is currently under review.'
- Newer filing (2026-05-13) specifies PRGN-2009 is 'non-replicating adenoviral vector-based immunotherapy' with more detailed mechanism description
- Removed:
- Older filing (2025-11-13) contains phrase 'Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization' which is removed in newer filing (2026-05-13)
- Older filing (2025-11-13) references phrase '"off-the-shelf" AdenoVerse immunotherapy platform' which is removed in newer filing (2026-05-13)
- Older filing (2025-11-13) states 'minimized UltraCAR-T spending and plan to focus on strategic partnerships to further advance UltraCAR-T programs' which is removed in newer filing (2026-05-13)
- Older filing (2025-11-13) references 'recurrent/metastatic cervical cancer' Phase 2 trial which is not mentioned in newer filing (2026-05-13)
- Older filing (2025-11-13) states 'We have reduced our focus on preclinical programs, while continuing select projects that we believe could provide further near-term validation of our technology platforms' which is removed in newer filing (2026-05-13)
- Older filing (2025-11-13) contains extensive RRP disease description ('can lead to severe voice disturbance, a compromised airway, and recurrent post-obstructive pneumonias' and 'repeated surgeries' details) which is condensed/removed in newer filing (2026-05-13)
- Older filing (2025-11-13) uses 'PRGN-2012' designation for Papzimeos product identifier in context of designations, newer filing (2026-05-13) uses 'zopapogene imadenovec-drba'
- Older filing (2025-11-13) states 'We have completed a Phase 1 clinical trial of PRGN-2009 as a monotherapy or' whereas newer filing (2026-05-13) describes Phase 2 trials instead
- Reworded:
- Older filing describes RRP disease 'caused by chronic human papillomavirus (HPV) 6 or HPV 11 infection' versus newer filing which states 'caused by chronic HPV 6 or HPV 11 infection' (shortened)
- Older filing (2025-11-13) states 'PRGN-2012 had been granted' versus newer filing (2026-05-13) which states 'Papzimeos had been granted' for designations
- Older filing states 'PRGN-2012 has received Orphan Drug Designation' versus newer filing which states 'zopapogene imadenovec-drba has received Orphan Drug Designation'
- Older filing describes PRGN-2009 as 'an investigational AdenoVerse immunotherapy' versus newer filing which specifies 'an investigational non-replicating adenoviral vector-based immunotherapy'
- Reference year changed from 'year ended December 31, 2024' in older filing to 'year ended December 31, 2025' in newer filing
- Notes:
- Text in newer filing appears truncated at end of PRGN-2009 section, limiting full comparison of clinical trial details
- Older filing text also appears truncated at final line, preventing complete comparison of Phase 1 trial information
Risk Factors
- Added:
- Added Item 5. Other Information section in newer filing (2026-05-13) disclosing Rule 10b5-1 trading arrangements adopted/amended by four officers during Q1 2026: Helen Sabzevari (CEO), Harry Thomasian Jr. (CFO), Rutul Shah (COO), and Phil Tennant (Chief Commercial Officer), with aggregate securities ranging from 77,166 to 477,260 shares and sale eligibility dates of June 29, 2026
- Newer filing includes Exhibit 101 (Interactive Data File in Inline XBRL format) with detailed financial statements and notes for Q1 2026 and 2025
- Newer filing includes Exhibit 104 (Cover Page Interactive Data File)
- Removed:
- Removed detailed 'Risks Related to Our Financial Position and Capital Needs' risk factor section from older filing (2025-11-13) that extensively described the $125.0 million Loan Agreement with BioPharma Credit entities, debt service obligations, covenants, and related risks
- Removed Item 2 disclosure in older filing regarding September 2025 conversion of 79,000 shares of 8.00% Series A Convertible Perpetual Preferred Stock into 54,937,411 common shares
- Removed exhibits 10.1 and 10.2 from older filing (Commercial Supply Agreement with Catalent Maryland and Loan Agreement dated September 3, 2025)
- Reworded:
- Older filing stated 'There are no additional material updates or changes to our risk factors since the filing of our Annual Report, except as discussed below' whereas newer filing states 'There are no additional material updates or changes to our risk factors since the filing of our Annual Report' (removed 'except as discussed below' qualifier, as no additional risks are now listed)
- Older Item 5 stated 'None.' whereas newer Item 5 contains detailed Rule 10b5-1 trading arrangement disclosures
- Notes:
- The newer filing represents Q1 2026 (quarter ended March 31, 2026) while older filing represents Q3 2025 (quarter ended September 30, 2025); the documents cover different fiscal periods and reporting dates
- The removal of the detailed debt risk factor and loan agreement exhibits in the newer filing may reflect that these risks were disclosed in an Annual Report referenced as applicable to both quarters, rather than being eliminated
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 12 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 3 sells ($1M) — 2 selling insiders
- Last 90 days0 buys · 12 sells ($6M) — 5 selling insiders
- Last 180 days0 buys · 12 sells ($6M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-06. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PGEN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding PGEN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 31,114,194
- Reported value $120,411,932
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PGEN had 42,044,362 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PGEN had 11.7% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.12 days to cover at the same settlement.
- Reported short interest (shares) 42,044,362
- Short interest (% of shares outstanding) 11.7%
- Prior settlement (shares) 41,025,860
- Reported change 2.48%
- Days to cover (reported) 11.12
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Novartis (NVS)
- Gilead Sciences (GILD)
- Bristol Myers Squibb (BMY)
- Bluebird Bio (BLUE)
- Iovance Biotherapeutics (IOVA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PGEN vs…
PRECIGEN INC is found in…
Frequently asked questions
What does PRECIGEN INC (PGEN) do?
Precigen is a commercial-stage biopharmaceutical company that develops precision medicine therapies using proprietary gene and cell technology platforms. Its primary focus is the advancement of treatments for immuno-oncology, autoimmune disorders, and infectious diseases, anchored by its first FDA-approved therapy, Papzimeos, for recurrent respiratory papillomatosis (RRP).
What sector is PRECIGEN INC (PGEN) in?
PRECIGEN INC (PGEN) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are PRECIGEN INC's (PGEN) competitors?
Notable peers of PRECIGEN INC (PGEN) include Novartis, Gilead Sciences, Bristol Myers Squibb, Bluebird Bio and Iovance Biotherapeutics. This peer set is informational only — not financial advice.
Is PRECIGEN INC (PGEN) overbought or oversold right now?
PRECIGEN INC (PGEN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PGEN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.